



NEWS RELEASE

## BIOSYENT TO PRESENT AT PLANET MICROCAP LAS VEGAS

FOR IMMEDIATE RELEASE

JUNE 15, 2026

**MISSISSAUGA, ONTARIO (June 15, 2026)** BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Las Vegas investor conference in Las Vegas, Nevada from June 16<sup>th</sup> to June 18<sup>th</sup>, 2026 at the Bellagio Hotel. Mr. René Goehrums, President and CEO of BioSyent, will be presenting in person to attendees at the conference on Wednesday, June 17<sup>th</sup> at 4:00pm PDT.

Mr. Goehrums will also be meeting with investors on a one-on-one basis during the conference on Wednesday, June 17<sup>th</sup> and on Thursday, June 18<sup>th</sup>. Subject to availability, these one-on-one meetings can be requested by registered attendees through the conference organizers.

### About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty healthcare products company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its Pharmaceutical and Oral Health businesses, both in Canada and internationally.

As of the date of this press release, the Company has 11,331,974 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit [www.tmxmoney.com](http://www.tmxmoney.com).

### For further information please contact:

Mr. René C. Goehrums  
President and CEO  
BioSyent Inc.  
E-Mail: [investors@biosyent.com](mailto:investors@biosyent.com)  
Phone: 905-206-0013  
Web: [www.biosyent.com](http://www.biosyent.com)

*This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.*